Genfit goes towards proof-of-concept
The share value of French specialist for cardiometabolic diseases Genfit S.A. (Loos/Lille) took a jump after the company announced its candidate drug GFT505 had met all efficacy endpoints in a pilot Phase II study involving 22 non-diabetic patients with insulin resistance and abdominal obesity (NCT 01271777). Following eight weeks of treatment with the PPAR a and d-modulator, patients’ insulin sensitivity in the liver had improved by 37%. Furthermore, markers for liver dysfunction like gGT, ALAT or ASAT were lowered, as well as those for inflammation such as fibrinogen or haptoglobin. Finally, plasma lipid parameters improved, according to the company. Genfit aims to establish the oral compound as a treatment for NALFD (non-alcoholic fatty liver disease), which affects at least 80% of diabetic patients, and NASH (non-alcoholic steatohepatitis), which affects 20-50% of them. Results from long-term tests in rats and monkeys suggest the compound does not provoke the severe side effects of other oral PPARg diabetes drugs. Unlike glitazones or glitazars, GFT505 did not induce cardiac hypertrophy, mortality, weight gain or edema after six months of treatment.